Vol 17, No 5 (2021)
Case report
Published online: 2021-06-10

open access

Page views 6250
Article views/downloads 482
Get Citation

Connect on Social Media

Connect on Social Media

Recurrent Her-2 positive occult breast cancer presenting with zosteriform cutaneous metastases: a case report

Mehmet Zahid Kocak1, Murat Araz1, Mustafa Karaagac1, Dilek Caglayan1, Mustafa Korkmaz1, Aykut Demirkiran1
Oncol Clin Pract 2021;17(5):229-231.

Abstract

Various cutaneous metastasis patterns are described in breast cancer. Zosteriform metastases are rare cutaneous metastases, which appear in a dermatomal distribution. A 66-year woman presented with a 1-month history of nodular lesions on the left posterior hemithorax area. Biopsy was reported as human epidermal growth factor receptor (Her) 2 positive, hormone receptor-negative breast carcinoma metastasis. Dual blockade therapy targeting Her-2 overexpression was initiated for the patient. Treatment response was obtained after 3 cycles. There was a significant improvement in skin lesions. Zosteriform cutaneous metastases can be the early sign of systemic spread and can show an initial response to therapy. Therefore, physicians should perform an exhaustive physical examination including that of skin.

Article available in PDF format

View PDF Download PDF file

References

  1. Pipkin CA, Lio PA. Cutaneous manifestations of internal malignancies: an overview. Dermatol Clin. 2008; 26(1): 1–15, vii.
  2. Lookingbill DP, Spangler N, Helm KF. Cutaneous metastases in patients with metastatic carcinoma: a retrospective study of 4020 patients. J Am Acad Dermatol. 1993; 29(2 Pt 1): 228–236.
  3. De Giorgi V, Grazzini M, Alfaioli B, et al. Cutaneous manifestations of breast carcinoma. Dermatol Ther. 2010; 23(6): 581–589.
  4. Moore S. Cutaneous metastatic breast cancer. Clin J Oncol Nurs. 2002; 6(5): 255–260.
  5. Araújo E, Barbosa M, Costa R, et al. A First Sign Not to be Missed: Cutaneous Metastasis from Breast Cancer. Eur J Case Rep Intern Med. 2020; 7(1): 001356.
  6. Sariya D, Ruth K, Adams-McDonnell R, et al. Clinicopathologic correlation of cutaneous metastases: experience from a cancer center. Arch Dermatol. 2007; 143(5): 613–620.
  7. Casimiro LM, Corell JJV. Metástasis cutáneas de neoplasias internas. Med Cutan Iber Lat Am. 2009; 37: 117–129.
  8. LeSueur BW, Abraham RJ, DiCaudo DJ, et al. Zosteriform skin metastases. Int J Dermatol. 2004; 43(2): 126–128.
  9. Virmani NC, Sharma YK, Panicker NK, et al. Zosteriform skin metastases: clue to an undiagnosed breast cancer. Indian J Dermatol. 2011; 56(6): 726–727.
  10. Sittart JA, Senise M. Cutaneous metastasis from internal carcinomas: a review of 45 years. An Bras Dermatol. 2013; 88(4): 541–544.
  11. Noguchi E, Kamio T, Kamio H, et al. Efficacy of lapatinib monotherapy on occult breast cancer presenting with cutaneous metastases: A case report. Oncol Lett. 2014; 8(6): 2448–2452.
  12. Pizzuti L, Sergi D, Barba M, et al. Unusual long-lasting cutaneous complete response to lapatinib and capecitabine in a heavily pretreated HER2-positive plurimetastatic breast cancer patient. Tumori Journal. 2018; 99(3): e127–e130.
  13. Deeken JF, Löscher W. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res. 2007; 13(6): 1663–1674.
  14. Niederkorn JY. See no evil, hear no evil, do no evil: the lessons of immune privilege. Nat Immunol. 2006; 7(4): 354–359.
  15. Gilhar A, Paus R, Kalish RS. Lymphocytes, neuropeptides, and genes involved in alopecia areata. J Clin Invest. 2007; 117(8): 2019–2027.
  16. Graziano V, Scognamiglio MT, Zilli M, et al. Is the skin a sanctuary for breast cancer cells during treatment with anti-HER2 antibodies? Cancer Biol Ther. 2015; 16(12): 1704–1709.